Genexol® PM Inj.

Active Ingredient


Genexol PM is a patented new formulation of paclitaxel developed by Samyang.
The new formulation is free from toxic surfactant and allows significantly higher dosing of paclitaxel to the patients.


Breast Cancer
  1. 1) First-line treatment of metastatic or recurrent breast cancer.
  2. 2) Second-line treatment of metastatic breast cancer after failure of standard chemotherapy.
Lung Cancer
  1. 1) First-line treatment of locally advanced or metastatic non-small cell lung cancer.
Ovarian cancer
  1. 1) First-line treatment in combination with other chemotherapeutic agents.

Dosage and Administration

Breast Cancer

Genexol-PM is administered at an initial dose of 260mg/㎡ intravenously over 3 hours every 3 weeks.

Non-small cell lung cancer

Genexol-PM is administered over 3 hours intravenously according to the dose below, followed by cisplatin at a dose of 60mg/㎡ intravenously.

  • Dose of Genexol-PM for first cycle : 230mg/㎡
  • Dose of Genexol-PM for second cycle and more
Ovarian cancer

Genexol-PM is administered at an initial dose of 260mg/㎡ intravenously over 3 hours every 3 weeks,
followed by arboplatin AUC 5mg/mL·min. intravenously.


Paclitaxel 30mg /vial , 100mg /vial


The goal of polymeric micelle technology is to enhance solublization of water insoluble drugs to facilitate formulation of therapeutcally more effective products.

Samyang’s proprietary biodegradable polymers such as poly(ethylene glycol)-poly(lactic acid) block copolymers have specific functionality. These polymers have strong potential for the development of self-forming nanometer-size(<50nm) micelle particles which can be administered directly to the specific sites and release the incorporated or entrapped drug in a sustained manner. Samyang’s proprietary polymeric micelle technology is being evaluated as a potential formulation strategy for systemic or local delivery of highly water insoluble drugs.

Testing to date has demonstrated significant pharmaceutical and biological advantages for polymeric micelle formulations as compared to standard preparations. The technology enables development of pharmaceutically acceptable formulations with enhanced stability and improved bioavailability of highly water insoluble drugs. Additional potential of the technology may be realized for manipulating pharmacokinetic parameters and distribution of drug in tissues.